Sudeep Pharma Limited has announced an earnings call to discuss the operational and financial performance for the fourth quarter and financial year ended March 31, 2026. The conference is scheduled for Friday, May 22, 2026, at 11:00 AM IST, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Agenda

The earnings call follows a Board of Directors meeting scheduled for Thursday, May 21, 2026. The board will convene to consider and approve the audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2026. Additionally, the board will evaluate the recommendation of a final dividend for FY2025-26, if any.

Earnings Call Details

The management team will address analysts and investors regarding the company's performance. Key participants include Mr. Sujit Bhayani, Managing Director; Mr. Shanil Bhayani, Director; and Mr. Ketan Vyas, Chief Financial Officer. Stakeholders are requested to pre-register for the event using the provided link.

Trading Window Closure

In compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for designated insiders has been closed since Wednesday, April 1, 2026. The window will remain shut until 48 hours after the declaration of the financial results, specifically until Saturday, May 23, 2026.

Sudeep pharma Limited has filed its quarterly compliance certificate with stock exchanges for the quarter ended March 31, 2026, in accordance with SEBI (Depositories and Participants) Regulations, 2018. The pharmaceutical company submitted the mandatory documentation to both the National Stock Exchange and BSE Limited on April 10, 2026.

Regulatory Compliance Certificate

The certificate was issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 by the company's registrar and share transfer agent, MUFG Intime India Private Limited (formerly Link Intime India Private Limited). The compliance document covers the quarter ended March 31, 2026.

Share Transfer Agent Confirmation

MUFG Intime India Private Limited, serving as the registrar and share transfer agent, confirmed in their certificate that no demat requests were received for processing during the quarter ended March 31, 2026. The registrar stated that all shares of Sudeep Pharma Limited are held in electronic mode only, eliminating the need for any dematerialization processing.

The confirmation was signed by Damodar Kambli, Assistant Vice President at MUFG Intime India Private Limited, and bears reference number CSC/SUDEEP/2026. MUFG Intime India Private Limited operates from their registered address at C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai.

Company Secretary Filing

Company Secretary and Compliance Officer Dimple Mehta (Membership No. F13184) digitally signed and submitted the compliance certificate to both stock exchanges. The filing ensures the company meets its regulatory obligations under SEBI depositories regulations.

The pharmaceutical company, headquartered at 129/1/A, G.I.D.C. Estate, Nandesari, Vadodara, Gujarat, continues to maintain full compliance with SEBI regulations regarding depositories and participant requirements. The quarterly certificate submission represents standard regulatory practice for listed companies to confirm the status of their share dematerialization processes.